XML 79 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income and Expenses (Tables)
12 Months Ended
Dec. 31, 2021
Analysis of income and expense [abstract]  
Cost of Sales

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Cost of sales related to COVID-19 vaccine revenues

 

€2,855.6

 

€35.6

 

€—

Cost related to other sales

 

55.9

 

23.7

 

17.4

Total

 

€2,911.5

 

€59.3

 

€17.4

Research and Development Expenses

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Purchased services

 

€572.6

 

€359.9

 

€65.6

Wages, benefits and social security expense

 

233.1

 

126.3

 

83.2

Laboratory supplies

 

53.8

 

107.8

 

37.2

Depreciation and amortization

 

32.9

 

30.2

 

27.5

Other

 

56.8

 

20.8

 

13.0

Total

 

€949.2

 

€645.0

 

€226.5

Sales and Marketing Expenses

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Purchased services

 

€26.5

 

€10.9

 

€0.2

Wages, benefits and social security expense

 

4.3

 

1.6

 

1.9

Other

 

19.6

 

2.0

 

0.6

Total

 

€50.4

 

€14.5

 

€2.7

General and Administrative Expenses

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Wages, benefits and social security expense

 

€90.5

 

€33.0

 

€19.1

Purchased services

 

70.2

 

26.0

 

6.4

Insurance premiums

 

30.4

 

4.8

 

1.1

IT and office equipment

 

25.1

 

7.4

 

4.6

Depreciation and amortization

 

7.3

 

5.1

 

4.9

Other

 

62.3

 

17.7

 

9.4

Total

 

€285.8

 

€94.0

 

€45.5

Other Operating Expenses

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Loss on derivative instruments at fair value through profit or loss

 

€86.3

 

€—

 

€—

Other

 

8.1

 

2.4

 

0.7

Total

 

€94.4

 

€2.4

 

€0.7

Other Operating Income

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Foreign exchange differences, net

 

€446.3

 

€—

 

€—

Government grants

 

137.2

 

239.0

 

1.5

Income from derivative instruments at fair value through profit and loss

 

5.7

 

—

 

—

Bargain purchase

 

2.2

 

7.0

 

—

Other

 

7.0

 

4.5

 

1.2

Total

 

€598.4

 

€250.5

 

€2.7

Changes Regarding Government Grants

The following table illustrates the changes regarding the government grants, including the government grant initiated by the BMBF:

 

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

As of January 1

 

€92.0

 

€—

 

€—

Received during the year

 

48.2

 

331.0

 

1.5

Released to the consolidated statements of profit or loss

 

  (137.2)

 

  (239.0)

 

  (1.5)

As of December 31

 

€3.0

 

€92.0

 

€—

Total current

 

3.0

 

92.0

 

—

Total non-current

 

—

 

—

 

—

Finance Income

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Foreign exchange differences, net

 

€66.2

 

€—

 

€2.3

Interest income

 

1.5

 

1.6

 

1.8

Total

 

€67.7

 

€1.6

 

€4.1

Finance Expense

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Fair value adjustments of financial instruments measured at fair value

 

€277.8

 

€17.3

 

€—

Amortization of financial instruments

 

21.9

 

3.1

 

0.3

Interest expenses related to lease liabilities

 

2.9

 

2.0

 

1.7

Interest expenses related to financial assets

 

2.5

 

—

 

—

Foreign exchange differences, net

 

—

 

42.6

 

—

Total

 

€305.1

 

€65.0

 

€2.0

Employee Benefits Expense

 

 

Years ended
December 31,

(in millions)

 

2021

 

2020

 

2019

Wages and salaries

 

€345.9

 

€160.7

 

€98.7

Social security costs

 

31.7

 

17.9

 

12.3

Pension costs

 

1.2

 

0.8

 

0.5

Total

 

€378.8

 

€179.4

 

€111.5